Day Trading Reports
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Day Trading Reports

Politics

Dr. Oz becomes next head of Medicare and Medicaid Services following approval from full Senate

by admin April 4, 2025
April 4, 2025
Dr. Oz becomes next head of Medicare and Medicaid Services following approval from full Senate

Dr. Mehmet Oz will serve as the next administrator of the Centers for Medicare and Medicaid Services after the full Senate voted along party lines to confirm his nomination on Thursday. 

The former daytime TV doctor turned politician will be in charge of nearly $1.5 trillion in federal healthcare spending. His duties will entail overseeing Medicare, Medicaid and the Children’s Health Insurance Program (CHIP), including directing decisions related to how the government covers procedures, hospital stays and medication, as well as the reimbursement rates at which healthcare providers get paid for their services.   

Medicare is a federal healthcare program for seniors aged 65 and up, and currently provides coverage to about 65 million Americans, according to the Center for Medicare Advocacy. Medicaid, a public health assistance program for people with low incomes, covers roughly 72 million Americans, according to Medicaid.gov. Meanwhile, CHIP, which provides free or low-cost health coverage for eligible low-income children and family members, assists around 7.2 million individuals. 

A graduate of Harvard University, Oz received medical and business degrees from the University of Pennsylvania. He is a former heart surgeon who saw his fame rise through his appearances on daytime television, including ‘The Oprah Winfrey Show,’ and 13 seasons of ‘The Dr. Oz Show.’

Oz later transitioned into politics, launching an unsuccessful bid for Pennsylvania’s open Senate seat in 2022. He lost to John Fetterman, then the state’s lieutenant governor.

‘Dr. Oz has a strong desire to modernize CMS and encourage healthy lifestyles for all Americans, including by focusing on the underlying causes of chronic disease and implementing innovative technologies,’ Senate Finance Committee Chairman Sen. Mike Crapo, R-Idaho, said Thursday.

Crapo, who led Oz’s nomination process at the committee level, commended Oz for his ‘diligence and accessibility’ throughout the process, including his willingness to answer ‘hundreds’ of questions for the record.

Those questions came from both Republicans and Democrats. They included asking about Oz’s stance on abortion, transgender medical treatments, Medicare privatization, prescription drug pricing and more. Potential financial conflicts of interest were also a concern among Democratic lawmakers throughout Oz’s confirmation process. Oz has committed to divesting any holdings that may pose an issue. 

Thursday’s confirmation comes as the Trump administration continues to work to finalize the rest of its political appointments, including notably the president’s pick to be the next United Nations ambassador and his pick for director of the Consumer Financial Protection Bureau. 

Per The Washington Post’s ‘political appointee tracker,’ there are currently still 233 nominees being considered by the Senate.

This post appeared first on FOX NEWS

previous post
Trump confirms National Security Council firings as Waltz’s Signal chat woes snowball
next post
Trump publicly backs France’s far-right figurehead Le Pen after her conviction

Related Posts

Senate confirms Doug Burgum to lead the Department...

January 31, 2025

Trump says US will ‘take a pass’ on...

April 19, 2025

Joe Biden diagnosed with ‘aggressive form’ of prostate...

May 19, 2025

Senior House Republican eviscerates Dems for ‘fear campaign’...

May 13, 2025

Trump unveils sanctions against International Criminal Court for...

February 7, 2025

Trump world fires back at Politico over report...

April 25, 2025

Trump praised for getting NATO allies to bolster...

March 14, 2025

US-Ukraine inching toward mineral deal amid last-minute roadblocks

May 1, 2025

Iran talks in Rome not happening this weekend...

May 2, 2025

Trump’s most vulnerable nominees RFK Jr, Tulsi Gabbard...

January 27, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Forum Energy Metals and Global Uranium Announce Exploration Update on Drill Targeting, Northwest Athabasca Project, Saskatchewan

      January 31, 2025
    • 2

      Mega M&A: Rio Tinto-Glencore Merger Sparks Chatter

      January 28, 2025
    • 3

      Excellent 90% recoveries at Cork Tree Well & Board Update

      February 17, 2025
    • 4

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 5

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: daytradingreports.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 daytradingreports.com | All Rights Reserved